Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.54 |
| ▸ | FABP7 | O15540 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157204 | 1.00 | FABP5 (0.54) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL3576113 | 1.00 | FABP5 (0.54) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL30510365 | 1.00 | FABP5 (0.54) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL30510380 | 1.00 | FABP5 (0.54) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL1830867 | 1.00 | FABP5 (0.54) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL30510279 | 1.00 | FABP5 (0.54) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL4612189 | 0.86 | FABP5 (0.46) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL1335555 | 0.86 | FABP5 (0.46) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL1334889 | 0.86 | FABP5 (0.46) | FABP5FABP7KMT2AACEEPHX2 | |
| SCHEMBL16153163 | 0.86 | FABP5 (0.46) | FABP5FABP7KMT2AEPHX2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | ALBIUS SCIENCES ALPHA PRIVATE LIMITED (SG) | 2024-10-03 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4361148-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | Albius Sciences Alpha Private Limited (SG) | 2024-05-01 | — | — | EP | disclosed |
| CN-117730079-A | Heterocyclyl-substituted polyheterazoles derivatives as medicaments for the treatment and/or prophylaxis of RSV infections | 亚博思生物科技(第一)有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11623012-B2 | Bicyclic peptide ligands specific for EphA2 | Bicyclerd Limited (GB) | 2023-04-11 | — | — | US | disclosed |
| WO-2022270628-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | 国立大学法人 大分大学 | 2022-12-29 | — | — | WO | disclosed |
| EP-2970390-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151634-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-1392721-A1 | PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002079234-A1 | PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623012-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, EPHB3 | FABP5 1653/4885FABP7 1022/4885KMT2A 1139/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FABP5 4094/4885FABP7 4602/4885KMT2A 3145/4885 |
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | RSU1, TSLP, HAVCR2 | FABP5 4130/4885FABP7 4049/4885KMT2A 2365/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FABP5 4094/4885FABP7 4602/4885KMT2A 3145/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | FABP5 4026/4885FABP7 4376/4885KMT2A 4757/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | FABP5 4094/4885FABP7 4602/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.